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Summary
Antiphospholipid antibodies are a recognised prothrombotic risk factor associated with acute ischaemic infarction. Most autoimmune
diseases are rare in infants, and in the neonatal period, autoimmunity is related to transplacental passage of maternal immunoglobulin G
autoantibodies. Distinguishing between de novo and acquired autoimmunity has important therapeutic implications and is crucial for
determining the prognosis. We present a case of a neonatal thrombotic stroke associated with de novo synthesis of antiphospholipid
antibodies, a homozygous 1298C/C methylene-tetrahydrofolate reductase mutation and a double-homozygous plasminogen activator
inhibitor 1 polymorphism (PAI-1 844A/A and 675 4G/4G), which may have increased the final thrombotic risk. Her mother was not positive
for antiphospholipid antibodies. The authors highlight an unequivocal evidence of a de novo case of paediatric antiphospholipid antibody
syndrome and emphasise the need for a thorough investigation in cases of neonatal stroke including molecular thrombophilia study.
BACKGROUND
Antiphospholipid syndrome (aPS) is a multisystem auto-
immune disorder characterised by a combination of arterial
and venous thrombosis, recurrent fetal loss, thrombocyto-
penia and the persistence of elevated titres of circulating
antiphospholipid antibodies (aPL), namely lupus anti-
coagulant (LA) and/or anticardiolipin antibodies (aCL).1 2
aPL are a recognised prothrombotic risk factor associated
with acute ischaemic infarction.3 Most autoimmune dis-
eases are rare in infants, and in the neonatal period, auto-
immunity is related to transplacental passage of maternal
IgG autoantibodies.4 The rate of stroke is higher in the
primary aPS patients, who are also younger at presenta-
tion.3 Distinguishing between de novo and acquired auto-
immunity has important therapeutic implications and is
crucial for determining the prognosis. The concomitant
presence of aPL and prothrombotic gene mutations serve as
a ‘two-hit’ model trigger for the occurrence of stroke.2 5
Herein, we present a case of a neonatal thrombotic stroke
with de novo synthesis of aPL associated with homozy-
gous 1298C/C methylenetetrahydrofolate reductase
(MTHFR) mutation and a double-homozygous 844A/A
and 675 4G/4G plasminogen activator inhibitor 1 (PAI-1)
polymorphism, which may have increased the final throm-
botic risk. Her mother was not positive for aPL.
CASE PRESENTATION
A girl was born at 40 weeks of gestational age by caesarean
section after an unremarkable pregnancy with an Apgar
index of 9 and 10, in the first and fifth minutes, respect-
ively. There was no family history of precocious stroke,
coagulation disorders or autoimmune disease. At 8 h of life,
she began multifocal clonic seizures. The neurological
examination revealed a left-sided hemiparesis including
face. Cerebral MRI showed an acute ischaemic stroke of
the right caudate and lenticular nucleus, with extension to
the cerebral peduncle (figure 1). MR angiography was
normal. Further investigation revealed a normal echocar-
diogram and infection was excluded; she presented normal
full blood count, coagulation, renal and liver function,
and normal serum complement and immunoglobulins.
Figure 1 Acute ischaemic stroke of the right caudate and
lenticular nucleus, with extension to the right cerebral peduncle.
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An extensive investigation of prothrombotic risk factors was
performed at the age of 3 months including: protein C,
protein S, antithrombin III, homocysteine, LA, aCL, β2
glycoprotein I (β2-GPI), antinuclear (ANA) and antidouble-
stranded-DNA antibodies (ds-DNA). We also carried out the
genotyping for factor V Leiden mutation, MTHFR and
PAI-1 polymorphism.
Results of serology for aPL has identified aCL IgG
mildly elevated (17.5 GPL/ml); an elevated β2-GPI IgG
(133 U/ml) and a positive LA. aPL IgM for aCL and
β2-GPI were negative. The thrombophilia genotyping
array disclosed homozygous 1298C/C MTHFR mutation
and a double homozygous PAI-1 844A/A and 675 4G/4G
polymorphism. At this point, maternal serum was nega-
tive for aPL and other autoantibodies.
Nine months later, the aCL IgG remained elevated
(26.9 GPL/ml) and LA continued positive, the β2-GPI IgG
was negative and appeared a positive ds-DNA antibody
(23.6 UI/ml).
At the beginning, seizures were managed with anticon-
vulsant therapy, which have been suspended at 3 months
of age, with no new events and with a normal EEG.
Antithrombotic treatment was started with aspirin. She
was followed through paediatric neurology, paediatric
rheumatology and child development consultations with
physical therapies.
At 12 months of age, her left-side strength had improved
showing only a monoparesis grade 3 of the left upper limb.
No further seizures or thrombosis had occurred.
DISCUSSION
This case accomplishes the revised criteria for the primary
antiphospoholipid antibody syndrome with clinical evi-
dence of arterial vessel thrombosis coexisting with more
than one laboratory criteria.1 Paediatric aPS seems to be
rare and its role in paediatric stroke continues to be inves-
tigated.3 Although there is some clinical evidence of a
higher risk for thromboembolic events, an international
registry for paediatric aPS, showed that ischaemic stroke
was its initial manifestation in 26% of cases.2 In another
study, ischaemic stroke was also more prevalent in paedi-
atric patients compared with adults (25% vs 13.1%).4
Unequivocally, vascular thromboembolism is a major
clinical manifestation of aPS. It have been proposed that
other comorbid prothrombotic conditions may function as
a trigger for the occurrence of ischaemic stroke in paediatric
age, like a ‘second hit model’, explaining the high rate of
inherited thrombophilic defects and their combinations in
children with aPS.2 6 In our case, the homozygous 1298C/
C MTHFR mutation and the double homozygous PAI-1
844A/A and 675 4G/4G polymorphism support this
concept. The absence of maternal aPL and the results of
repeated testing for aPL in our patient corroborate the de
novo synthesis of aPL. Authors reported some differences
between primary aPS versus secondary aPs showing a stat-
istically significant higher frequency of ischaemic stroke in
the group of patients with primary aPS.4
In our patient, the presence of various prothrombotic
risk factors associated with a de novo primary aPS necessi-
tated an antithrombotic treatment. On this subject, there
are no trials evaluating the different efficacy of warfarin,
aspirin or heparin treatment in paediatric aPS.
There is still debate in which therapy is the most effect-
ive for secondary prevention of stroke with aPS.3 7 8 We
started antiaggregation with a low dose of aspirin (3 mg/
kg/day), without new thrombotic episodes observed.
The detection of ds-DNA antibody put us in alert for
the possibility of systemic lupus erythematosus (SLE),
knowing that girls with aPS should be monitored for
development of SLE,2 although to date, the child has not
developed other clinical or laboratory manifestations for
SLE.
In conclusion, this case emphasises the importance of a
complete evaluation of all prothrombotic risk factors in
neonatal ischaemic stroke, including thrombophilia geno-
typing tests for understanding the multifactorial patho-
genesis of neonatal ischaemic stroke.
Learning points
▸ In neonatal stroke, it is important to clarify all the risk
factors and possible causes.
▸ Primary antiphospoholipid antibody syndrome can be a
cause of neonatal stroke, and antiphospholipid
antibodies should be re-evaluated at least 12 weeks
after the first analysis.
▸ In neonatal ischaemic stroke, molecular study for
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